Neurim prevails against Mylan in suit over insomnia drug

Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Big Pharma

Questions on Neurim scope remain post-SPC ruling, say lawyers

25 March 2019 The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Neurim prevails against Mylan in suit over insomnia drug

More on this story

Editor's picks

Editor's picks

More features